Personal Account
Personal Account
About
The company is a clinical-stage biopharmaceutical entity that prioritizes patient care, specializing in the development of cell therapies for individuals afflicted with autoimmune diseases. Its mission is to deliver transformative therapeutic benefits to these patients, leveraging a patient-centric strategy, a comprehensive platform, and insights gained from treating immune disorders and the successful use of cell therapy in other medical fields. The company's approach to treating autoimmune diseases with cell therapy is bolstered by scientific publications detailing multiple autoimmune case studies using CD19 CAR T-cell treatment, as well as preliminary clinical data from ongoing trials demonstrating the transformative potential of these therapies. Such validation has charted a definitive course for the company to further the clinical progress of its flagship product, KYV-101, targeting two major categories of autoimmune disease: rheumatology and neurology.
___________________________
Number of employees: 50-100
Headquarters location: 5980 Horton St., STE 550 Emeryville, CA 94608, USA
_____________________________
Perfomance
| Revenues | $0.28 mil (last 12 months) |
| Net Income | $-48.2 mil (last 12 months) |
_____________________________
Potential
Creating “smarter” CAR T cells
Leveraging advances in CAR T engineering and insights from the use of conventional CAR T cell therapies for cancer, Kyverna is building a robust collection of cell therapy assets and tools to address multiple targets implicated in the pathogenesis of autoimmune diseases.
_____________________________
Events
(open links below)
Underwriters
Bain Capital Life Sciences, GordonMD Global Investments LP, Gilead Sciences, Westlake Village BioPartners, Vida Ventures, Northpond Ventures, RTW Investments, Insight Partners, CAM Capital, LYFE Capital, jVen Capital.